Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CC-292

Known as: Bruton's Tyrosine Kinase Inhibitor CC-292 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2019
2019
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been shown to be highly effective in patients with chronic lymphocytic… Expand
2017
2017
Ibrutinib is a first-in-class covalent inhibitor of Bruton tyrosine kinase (BTK) approved in the European Union and USA for the… Expand
  • figure 1
  • figure 2
  • figure 3
2017
2017
Correlating target engagement with in vivo drug activity remains a central challenge in efforts to improve the efficiency of drug… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
2016
2016
B-cell receptor (BCR) signaling plays a key role in the pathogenesis of B-cell malignancies, mediating the survival and… Expand
  • table 1
  • figure 1
  • figure 2
2016
2016
Additions of cysteine thiols to Michael acceptors underpin the mechanism of action of several covalent drugs (e.g., afatinib… Expand
2015
2015
Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… Expand
2014
2014
Bruton’s tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Introduction CC-292, an oral, highly selective, small-molecule irreversible-inhibitor of Btk is under investigation for the… Expand